Nature4y
Enhanced immuno-viral therapy for solid tumors
EpCAM is a validated therapeutic target for a range of tumor types including breast cancer, non-small-cell lung cancer and prostate cancer. Manufacturing of EpCAM-TEA-VV is underway, and IKT is ...
Morningstar1mon
LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
[iii],[iv] The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial ...
PharmiWeb1mon
Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
[iii], [iv] The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial ...